Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia

Published:January 25, 2019DOI:


      • New-onset atrial fibrillation (NOAF) is a common during hospitalization for CAP.
      • CHA2DS2-VASc score is an accurate predictor of NOAF in patients hospitalized for CAP.
      • A CHA2DS2-VASc >3 can identify patients at greater risk of NOAF.



      Cardiovascular events are common during hospitalization for community-acquired pneumonia (CAP), with new onset atrial fibrillation (NOAF) being the second most relevant complication. In this study, we aimed to investigate the role of CHA2DS2-VASc score in predicting NOAF during hospitalization for CAP.


      Patients admitted for CAP were prospectively assessed using CHA2DS2-VASc. The end-point of the study was the occurrence of any objectively documented episode of NOAF during hospitalization in patients that were in sinus rhythm at hospital admission.


      Of 468 patients enrolled (median age 76 years), 48 (10.3%) experienced NOAF during hospitalization. They were older, had more comorbidities, more severe pneumonia, and higher CHA2DS2-VASc than those who remained in sinus rhythm (4.4 ± 1.6 vs 3.4 ± 1.9, respectively; p < .0001). There was a direct relationship between CHA2DS2-VASc score and risk of NOAF. At ROC curve analysis, a CHA2DS2-VASc score > 3 was the most accurate cut-off for prediction of NOAF (AUC 0.653; 95% CI 0.577–0.729; p = .001). In two different multivariable models, each CHA2DS2-VASc point increase and a score > 3 both were independently associated with NOAF (HR 1.3; 95% CI 1.09–1.55; p = .003 and 2.3; 95% CI 1.19–4.44; p = .007, respectively).


      CHA2DS2-VASc score is an accurate and independent predictor of NOAF in patients with CAP, and a score > 3 features a population at high risk of developing the arrhythmia during hospitalization. This simple and effective tool should be incorporated in the evaluation of patients hospitalized for CAP, with implications ranging from arrhythmic prevention to anticoagulation management.



      AF (atrial fibrillation), CAP (community-acquired pneumonia), CHA2DS2-VASc (Congestive heart failure/left ventricular dysfunction, Hypertension, Age (≥ 75 years 2 points), Diabetes, Stroke/transient ischemic attack (2 points), Vascular disease, Sex category), CURB-65 (Confusion, Urea, Respiratory rate, Blood pressure, age >65 years), CV (cardiovascular), NOAF (new onset atrial fibrillation)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prina E.
        • Ranzani O.T.
        • Torres A.
        Community-acquired pneumonia.
        Lancet. 2015; 386: 1097-1108
        • Wang H.
        • Naghavi M.
        • Allen C.
        • et al.
        GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015.
        Lancet. 2016 Oct 8; 388: 1459-1544
        • File Jr., T.M.
        • Marrie T.J.
        Burden of community-acquired pneumonia in North American adults.
        Postgrad Med. 2010; 122: 130-141
        • Corrales-Medina V.F.
        • Musher D.M.
        • Shachkina S.
        • Chirinos J.A.
        Acute pneumonia and the cardiovascular system.
        Lancet. 2013; 381: 496-505
        • Corrales-Medina V.F.
        • Musher D.M.
        • Wells G.A.
        • Chirinos J.A.
        • Chen L.
        • Fine M.J.
        Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.
        Circulation. 2012 Feb 14; 125: 773-781
        • Violi F.
        • Cangemi R.
        • Falcone M.
        • Taliani G.
        • Pieralli F.
        • Vannucchi V.
        • et al.
        Corrales-Medina VF.; SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) study Group. Cardiovascular Complications and Short-term Mortality Risk in Community-acquired Pneumonia.
        Clin Infect Dis. 2017 Jun 1; 64: 1486-1493
        • Restrepo M.I.
        • Reyes L.F.
        • Anzueto A.
        Complication of community-acquired pneumonia (including cardiac complications).
        Semin Respir Crit Care Med. 2016; 37: 897-904
        • Mandal P.
        • Chalmers J.D.
        • Choudhury G.
        • Akram A.R.
        • Hill A.T.
        Vascular complications are associated with poor outcome in community-acquired pneumonia.
        QJM. 2011; 104: 489-495
        • Cangemi R.
        • Calvieri C.
        • Falcone M.
        • Bucci T.
        • Bertazzoni G.
        • Scarpellini M.G.
        • et al.
        Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events.
        Am J Cardiol. 2015; 116: 647-651
        • Kirchof P.
        • Benussi S.
        • Kotecha D.
        • Ahisson A.
        • Atar D.
        • Casadei B.
        • et al.
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Europace. 2016 Nov; 18: 1609-1678
        • Melgaard L.
        • Gorst-Rasmussen A.
        • Lane D.A.
        • Rasmussen L.H.
        • Larsen T.B.
        • Lip G.Y.
        Assessment of the CHA2DS2-VASc score in predicting Ischemic Stroke, Thromboembolism, and death in patients with Heart failure with and without Atrial Fibrillation.
        JAMA. 2015; 314: 1030-1038
        • Polenz G.F.
        • Leiria T.L.
        • Essebag V.
        • Kruse M.L.
        • Pires L.M.
        • Nogueira T.B.
        • et al.
        CHA2 DS2 VASc score as a Predictor of Cardiovascular events in Ambulatory patients without Atrial Fibrillation.
        Pacing Clin Electrophysiol. 2015 Dec; 38: 1412-1417
        • Ntaios G.
        • Lip G.Y.
        • Makaritsis K.
        • Papavasileiou V.
        • Vemmou A.
        • Koroboki E.
        • et al.
        CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
        Neurology. 2013 Mar 12; 80: 1009-1017
        • Barkas F.
        • Elisaf M.
        • Korantzopoulos P.
        • Tsiara S.
        • Liberopoulos E.
        The CHADS2 and CHA2DS2-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels.
        Int J Cardiol. 2017 Aug 15; 241: 194-199
        • Chen Y.L.
        • Cheng C.L.
        • Huang J.L.
        • Yang N.I.
        • Chang H.C.
        • Chang K.C.
        • et al.
        Mortality prediction using CHADS2/CHA2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation.
        Medicine (Baltimore). 2017 Oct; 96e8338
        • Violi F.
        • Carnevale R.
        • Calvieri C.
        • Nocella C.
        • Falcone M.
        • Farcomeni A.
        • et al.
        Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia.
        Thorax. 2015; 70: 961-966
        • Benjamin E.J.
        • Levy D.
        • Vaziri S.M.
        • D'Agostino R.B.
        • Belanger A.J.
        • Wolf P.A.
        Independent Risk Factors for Atrial Fibrillation in a Population-based Cohort the Framingham Heart Study.
        JAMA. 1994; 271: 840-844
        • Feinberg W.M.
        • Blackshear J.L.
        • Laupacis A.
        • Kronmal R.
        • Hart R.G.
        Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications.
        Arch Intern Med. 1995; 155: 469-473
        • Go A.S.
        • Hylek E.M.
        • Phillips K.A.
        • Chang Y.
        • Henault L.E.
        • Selby J.V.
        • et al.
        Prevalence of Diagnosed Atrial Fibrillation in adults National Implications for Rhythm Management and Stroke Prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
        JAMA. 2001; 285: 2370-2375
        • Meschia J.F.
        • Bushnell C.
        • Boden-Albala B.
        • Braun L.T.
        • Bravata D.M.
        • Chaturvedi S.
        • et al.
        Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2014 Dec; 45: 3754-3832
        • Bolognesi M.
        • Bolognesi D.
        Ciprofloxacin-induced paroxysmal atrial fibrillation.
        OA Case Reports. 2014 Mar 08; 3: 24
        • CS van der Hooft
        • Heeringa J.
        • van Herpen G.
        • Kors J.A.
        • Kingma J.H.
        • Stricker B.H.
        Drug-induced atrial fibrillation.
        J Am Coll Cardiol. 2004 Dec 7; 44: 2117-2124